Bristol, United Kingdom
CytoSeek is a pioneering United Kingdom-based company, founded in 2017, that operates within the Biotechnology, Life Sciences, and Pharmaceutical industries. With the slogan "A cell-therapy technology company developing artificial membrane-binding proteins for oncology and regenerative medicine," CytoSeek is firmly placing itself at the intersection of advanced cellular therapies aimed at addressing critical medical needs.
The company’s core innovation is its proprietary cell membrane augmentation technology. This breakthrough allows for the addition of novel functionalities to therapeutic cells, which has potential applications in both oncology and regenerative medicine. CytoSeek is actively conducting proof of principle studies to demonstrate these enhancements within cell therapies for cancer, underpinning its mission to revolutionize next-generation advanced therapies.
Currently in the phase of seeking partnerships, CytoSeek aims to collaborate with other cell therapy firms to propel its products towards clinical applications, with the long-term goal of significantly improving human health outcomes. Notably, the company has yet to announce its latest investment rounds, implying untapped potential for venture capital engagement.
